Immunovant Cash Flow Statement Analysis

Operating, investing, and financing activities in millions USD

Scroll to see more
Cash flow statement showing operating, investing, and financing activities for Immunovant, Inc. (IMVT) - Annual data in millions USD
BreakdownFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Period EndingDec 2025Mar 2024Mar 2023Mar 2022Mar 2021Mar 2020
Operating Activities
Net Income-413.84-259.34-210.96-156.73-107.43-66.39
Depreciation & Amortization0.381.360.190.131.000.02
Stock Based Compensation49.4941.1232.3034.2418.820.00
Change in Working Capital-12.033.80-10.8515.145.364.90
Change in Accounts Receivable2.97-4.5811.76-11.63-0.600.00
Change in Accounts Payable10.685.46-17.1216.251.250.00
Change in Other Working Capital-25.691.13-5.9510.614.420.00
Other Operating Activities0.1339.941.131.1117.748.46
Net Cash from Operating Activities-375.87-214.23-188.19-106.11-83.33-53.36
Investing Activities
Capital Expenditures-0.760.36-0.20-0.250.210.03
Net Cash from Investing Activities-0.76-0.36-0.20-0.25-0.21-0.03
Financing Activities
Debt Repayment0.000.000.000.00-3.19-2.50
Common Stock Issued454.49-6.0171.16200.13-1.240.00
Other Financing Activities0.00-6.01-0.270.131.10109.07
Net Cash from Financing Activities454.49472.4370.89200.13383.11141.57
Summary
Effect of Forex Changes on Cash0.750.990.22-0.090.000.00
Net Change in Cash78.61257.84-117.2993.67299.5888.18
Cash at Beginning of Period635.37376.53493.82400.15100.576.99
Cash at End of Period713.97376.53376.53400.15100.5795.16
Free Cash Flow-376.63-214.59-188.39-106.37-83.54-53.39
Supplemental Disclosures
Income Taxes Paid1.200.510.000.000.170.06